1. Trang chủ
  2. » Kỹ Thuật - Công Nghệ

Pharmaceutical Substances Syntheses, Patents, Applications - Part 34 ppt

10 452 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 10
Dung lượng 225,35 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

HCI olternative preporotion of intermediate 11 cytosine 5-fluoro-2-0.4-N-bis- trirnethylsilylcytosine V References: a EP 602 454 Hoffmann-La Roche: appl... racemate resolution of DL

Trang 1

Canthaxanthin C

retinal

(cf betacaratene synthesis)

0

4-ocetoxyretinol (I)

(4-ocetoxyretinyl)triphenyl-

phosphanium chloride (11)

trans-isozeoxanthin (111)

Reference(s):

US 3 31 1 656 (Roche; 28.3.1967; appl 12.5.1964)

Surmatis, J.D et al.: Helv Chim Acta (HCACAV) 53,974 (1970)

I

alternative syntheses:

DOS 2 037 935 (Roche; appl 30.7.1970; CH-prior 1.8.1969)

US 4 000 198 (Roche; 28.12.1976; appl 9.6.1975)

DOS 2 625 259 (Roche; appl 4.6.1976; USA-prior 9.6.1975)

Forrnulation(s): gel 10 mgl600 mg; 15 mgl900 mg

Trang 2

332 C Capecitabine

Trade Name(s):

F: Phenoro "Roche" (Prod

Roche S.A.R.L.)-comb

with betacarotene

Capeci tabine

(Ro-09- 1978)

RN: 154361 -50-9 MF: C,5H22FN306 MW: 359.35

CN: 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine

H C 0 CH3

,

doxifluridine

(q )

5'-deoxy-5-fluoro-

cytidine (I)

pentyl chloro-

formote (In)

ATC: LOlBC06 Use: anticancer, orally active prodrug of

doxifluridine

cytidine (11)

Trang 3

,r-

pyridine

CH2C12

*

1 NaOH CH30H

- 1 O0C

2 HCI

olternative preporotion of intermediate 11

cytosine

5-fluoro-2-0.4-N-bis- (trirnethylsilyl)cytosine (V)

Reference(s):

a EP 602 454 (Hoffmann-La Roche: appl 1.12.1993; EP-prior 18.12.1992)

US 5 472 949 (Hoffmann-La Roche; 5.12.1995; EP-prior 18.12.1992)

b US 5 476 932 (Hoffmam-La Roche; 19.12.1995; USA-prior 26.8.1994)

compositions of interleukin and pyrimidine nucleosides:

WO 9 637 214 (Hoffmann-La Roche; appl 15.5.1996; EP-prior 26.5.1995)

Formulation(s): tabl 150 mg, 500 mg

Trade Name(s):

USA: Xeloda (Roche; 1998)

Copecitobine

I

Capreomycin

(Caprenomy cin)

RN: 11003-38-6 MF: C2,H,N,,08 MW: 668.72

LD,: 238 mglkg (M, i.v.)

CN: capreomycin (mixture of capreomycin IB, IA, IIA and IIB)

ATC: J04AB30 Use: tuberculostatic, peptide antibiotic

sulfate

RN: 1405-37-4 MF: H2S0, unspecificd MW: unspecified EINECS: 215-776-8

LD,,: 250 mgkg (M, i.v.);

325 mg/kg (R, i.v.)

Trang 4

334 C Cautodiame

CH3

Capreomycin IB

From culture of Streptomyces capreolus by ion-exchange adsorption

Referertce(s):

US 3 143 468 (Eli Lilly; 4.8.1964; appl 25.5.1962; prior 2.1 1.1959)

Form~dation(s): vial 1 g

Trade Name(s):

D: Ogostal (Lilly); wfm J: Capastat (Shionogi; as

GB: Capastat (King; as sulfate) USA: Capastat (Dura)

Use: psychoregulant, sedative RN: 486-17-9 MF: C,,H,,NS, MW: 359.60 EINECS: 207-629-1

LD,,,: 72 mglkg (M, i.v.); 1630 mglkg (M, p.0.);

3800 mglkg (R, p.0.)

CN: 2-[[[4-(butylthio)phenyl]phenylmethyl]thio]-N,N-dimethylethanamine

hydrochloride

RN: 904-04-1 MF: C,,H,,NS, HCl MW: 396.06 EINECS: 212-992-4

LD,,,: 44 mglkg (M, i.v.)

and benzoyl chloride)

K

2 NaOH

1 -+

no)ethyl chloride H3f' '-"-'-'-'

Trang 5

Captopril C 335

Reference(s):

US 2 830 088 (O.H Hubner, P.V Petersen; 1958; DK-prior 1952)

Formulation(s): tabl 50 mg

Trade Name(s):

F: Covatine (Bailly)

Use: antihypertensive (ACE inhibitor) RN: 62571-86-2 MF: C9HI5NO3S MW: 217.29 EINECS: 263-607-1

LD,,: 663 mg/kg (M, i.v.); 2500 mg/kg (M, p.0.);

554 mglkg (R, i.v.); 4245 mglkg (R, p.0.)

CN: (S)-1-(3-mercapto-2-metl~yl-l-oxopropyl)-~-proline

CH3 H , C ~ S ~ C I C H 3

L-proline (Ill) benzyl

U N-benzyloxycorbonyl- chloroformote L-proline

N-benzyloxycarbonyl-L- L-proline tert-

proline tert-butyl ester (IV) butyl ester

H3C 0 y C H 3 separation of the diastereorners

vla the dicyclohexylarnine CF3COOH, anisole

"9 salt in ethyl acetote trifluoroacetic o c i b

O cooH

b

noyll-L-proline (VI)

Trang 6

336 C Captopril

1 OH-

nl + ,, 2 seporotion of t h e diostereorner B VI NH,, CH,OH

rnicrobiolog., e.g with Condido ruguso/FO-0750

Condido rugoso/FO-0591 Condido utilis

H3C +OOH /F0-0396 or other bioreogents

D(-)-3-hydroxy-

isobutyric ocid (VII)

C H 3

isobutyric

ocid

rnicrobiolog., in onology to isobutyric ocid

CH3 NoOH

,,I1 + 11, , O F '

SOC12, DMF

VII

0

D-3-chloro-2-methyl-

propionyl chloride (Wl)

Reference ( s ) :

a,b DOS 2 703 828 (Squibb; appl 3 1.1.1977; USA-prior 13.2.1976; 21.6.1976, 22.12.1976)

US 4 046 889 (Squibb; 6.9.1977; appl 13.2.1976)

US 4 105 776 (Squibb; 8.8.1978; prior 13.2.1976, 21.6.1976,22.12.1976)

US 4 154 840 (Squibb; 15.5.1979; prior 13.2.1976,21.6.1976,22.12.1976,9.3.1977)

US 4 154 935 (Squibb; 15.5.1979; prior 21.2.1978, 1.9.1978)

c GB 2 065 643 (Kanegafuchi; appl 1 l2.1980; J-prior 13.12.1979,28.12.1979, 8.3.1980)

US 4 460 780 (Kanegafuchi; 17.7.1984; J-prior 20.1.1982)

microbiological production of D-(-)-3-hydroxyisobutyric acid:

US 4 310 635 (Kanegafuchi; 12.1.1982; J-prior 6.1 1.1979, 14.2.1980,7.7.1980)

similar methods with D- or DL-3-halogeno-2-methylpropionic acids as intermediates:

Nam, D.H et al.: J Pharm Sci (JPMSAE) 73; 1843 (1984)

DE 3 049 273 (Egyt; appl 29.12.1980; HU-prior 29.12.1979)

US 4 332 725 (Egy t; 1.6.1982; HU-prior 29.12.1979)

GB 2 066 252 (Egyt; appl 29.12.1980; HU-prior 29.12.1979)

US 4 399 144 (Wyeth; 16.8.1983; GB-prior 30.4.1980)

alternative syntheses:

via 3-mercapto-2-D-methylpropionic acid:

US 4 384 139 (Kanegafuchi; 17.5.1983; J-prior 20.8.1980)

GB 2 082 174 (Kanegafuchi; appl 7.8.1981 ; J-prior 20.8.1980)

via 3-acylthio-2-D-methylpropionic acids:

EP 8 831 (OcC-Andeno; appl 31.8.1979; NL-prior 7.9.1978)

racemate resolution of DL-3-acy1thio-2-methy1propionic acids:

EP 35 81 1 (OcC-Andeno; appl 26.2.1981; NL-prior 6.3.1980)

US 4 346 045 (OcC-Andeno; 24.8.1982; NL-prior 6.3.1980)

US 4 297 282 (Sumitomo; 27.10.1981; J-prior 2.3.1979, 13.3.1979, 28.6.1979,25.7.1979)

racemization of L-3-acylthio-2-methylpropionic acids:

US 4 41 1 836 (Sumitomo; 25.10.1983; J-prior 13.3.1979)

Trang 7

Carazolol C

I 337 1

pur$cation of captopril (removal of disuljide):

U S 4 332 726 (Squibb; 16.1982; appl 25.8.1980)

medical use for treatment of glaucoma:

IEP 99 239 (Squibb; appl 6.7.1983; USA-prior 6.7.1982)

combination with diuretics:

DOS 2 854 316 (Squibb; appl 15.12.1978; USA-prior 27.12.1977)

controlled-release formulation:

US 4 505 890 (Squibb; 19.5.1985; appl 30.6.1983)

Trade Namefs):

D: Capozide (Bristol-Myers

Squibb; 1984)-comb with

hydrochlorothiazide

Lopirin (Bristol-Myers

Squibb; 1981)

Tensobon (Schwarz; 1983)

F: CaptCa (Bellon)-comb

Captolane (Bellon; 1984)

Ecazide (Bristol-Myers

Squibb)-comb

Lopril (Bristol-Myers Squibb; 1982) GB: Acepril (Ashbourne) Azecide (Ashbourne)- comb

Capoten (Biistol-Myers Squibb; 1981)

Capozide (Bristol-Myers Squibb)-comb

I: Acediur (Chidotti)-comb

Aceplus (Bristol-Myers Squibb)-comb

Accprcss (Guidotti) Capoten (Bristol-Myers Squibb; 1981)

J: Captoril (Sankyo; 1983) USA: Capoten (Bristol-Myers Squibb; 1981)

Capozide (Bristol-Myers Squibb; 1986)

Use: non-selective P-adrenoceptor blocker, antihypertensive, antianginal

RN: 57775-29-8 MF: C,,H2,N202 MW: 298.39 EINECS: 260-945-1

CN: l-(9H-carbazol-4-yloxy)-3-[(l-methylethyl)amino]-2-propanol

H

0 NaOH, dioxane

@ + U,.P

OH

Reference(s):

DOS 2 240 599 (Boehringer Mannh.; appl 18.8.1972)

GB 1 369 580 (Boehringer Mannh.; valid from 9.10.1974; D-prior 18.8.1972)

synthesis of 4-hydroxycarbazole:

DOS 2 928 483 (Boehringer Mannh., appl 14.7.1979)

Trang 8

338 C Carbachol

Trade Narne(s):

D: Conducton (Klinge)

Carbachol

(Carbacholine)

ATC: N07ABOI; SOIEBO2 Use: parasyrnpathomimetic RN: 51-83-2 MF: C,H,,CIN2O2 MW: 182.65 EINECS: 200-127-3

LD,,: 300 p g k g (M, i.v.); 15 m g k g (M, p.0.);

100 @/kg (R, i.v.); 40 mglkg (R, p.0.)

CN: 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanarninium chloride

Reference(s):

DRP 539 329 (E Merck AG; appl 1930)

DRP 553 148 (E Merck AG; appl 1930)

DRP 590 3 11 (E Merck AG; appl 1932)

Hayworth, R.D et a].: J Chern Soc (JCSOA9) 1947 176

trirnethyl-

alternative syntllesis from choline chloride:

US 2 374 367 (Merck & Co.; 1945; prior 1943)

Corbachol

Fomulation(s): amp 0.25 mg; tabl 2 rng

ornine

Trade Name(s):

D : Carbarnann (Mann) F: Iricoline (Lernatte et I: Mios (1ntes)-comb

Isopto-Carbachol (Alcon) Impto Carbachol (Alcon); USA: lsopto Carbachol Solut

comb

Use: antiepileptic, anticonvulsant RN: 298-46-4 MF: C,SH,,N,O MW: 236.27 EINECS: 206-062-7

LD,,: 529 mgfkg (M, p.0.);

1957 rnglkg (R, p.0.);

5620 rngkg (dog, p.0.)

CN: SH-dibenz[bJlazepine-5-carboxarnide

Trang 9

7

N-Carbamoyl-L-aspartic acid calcium salt C 339

5H-dibenz- phosgene

[b,f]azepine (1)

/ Carbamozrpinr

potassium

cyanate

Reference(s):

US 2 948 718 (Geigy; 9.8.1960; CH-prior 20.12.1957)

alternative synthesis:

DD 133 052 (R Miiller; appl 8.9.1977)

Formulation(s): s r tabl 200 mg, 400 mg; susp 100 mg;.tabl 200 mg

Trade Name(s):

D: Finlepsin (ASTA Medica Timonil (Desitin) J: Tegretol (Fujisawa) AWD; Boehringer Mannh.) F: Tegrttol (Novartis) USA: Epitol (Teva)

Sirtal (Merck Generika) GB: Tegretol (Novartis) Tegretol (Novartis) Tegretal (Novartis Pharma) I: Tegretol (Novartis)

N-Carbamoyl-L-aspartic acid calcium salt Use: psychoenergetic, tranquilizer (Calcii carbaspartas)

RN: 16649-79-9 MF: C5H,CaN,0, MW: 214.19 EINECS: 240-698-6

CN: N-(aminocarbony1)-L-aspartic acid calcium salt (1:l)

N-carbamoyl-baspartic acid

RN: 13 184-27-5 MF: CsHRN20s MW: 176.13 EINECS: 236-134-3

LD,,: >I g/kg (M, p.0.)

potassium L-aspartate

I KOCN

2 HCI

0 NH 3 CaCI,

KoK1;O~ b

cyanate

N-Carbamayl-L-aspadic

acid calcium salt

W

Jy,$?z cop+

- 0

0

Referencefs):

FR-M 6 376 (Roussel-Uclaf; appl 18.4.1967)

Trang 10

1

340 C Carbasalate calcium

Trade Name(s):

salt); wfm

Carbasalate calcium

(Calcium carbaspirin)

ATC: BOlAC08; N02BA15 Use: analgesic

RN: 5749-67-7 MF: Cl,Hl4CaO8 CH,N,O MW: 458.44 EINECS: 227-273-0

CN: 2-(acetyloxy)benzoic acid calcium salt compd with Urea (1 :1)

Reference(s):

Parrott, E.L.: J Pharm Sci (JPMSAE) 51, 897 (1962)

acetylsaiicylic

acid

calcium acetylsalicylate:

US 2 003 374 (Lee Labs.; 1935; appl 1932)

Carbasalate calcium

Formulation(s): tabl 500 mg

Trade Name(s):

D: Iromin (Omegin); wfm USA: Fiogesic (Sandoz); wfm

F: Solupsan (UPSA)

Ursinus Inlay-Tabs (Dorsey); wfm

Use: antihemorrhagic, hemostatic RN: 69-81-8 MF: CloHI,N4O3 MW: 236.23 EINECS: 200-717-0

LD,,,: >35.832 glkg (M, p.0.);

>17.280 glkg (R, p.0.)

CN: 2-(1,2,3,6-tetrahydro-3-hydroxy-1-methyl-6-oxo-5H-indol-5-ylidene)hydrazinecarb0xamide

epinephrine

(9 v.)

Carbazochrome

Reference(s):

US 2 506 294 (Soc Relge de 1'Azote et des Prod Chim.; 1950; B-prior 1943)

GB 806 908 (Labaz; appl 1957; USA-prior 1956)

US 3 244 591 (Endo Labs.; 5.4.1966; appl 10.8.1960)

oxidation of adrenaline with persulfate:

DOS 2 713 652 (Nippon Gohsei; appl 28.3.1977; J-prior 31.3.1976)

Ngày đăng: 02/07/2014, 02:20

TỪ KHÓA LIÊN QUAN